MBD European Technical Committee Novo Nordisk A/S, Denmark

Introduction Peter Bender Christoffersen Specialist for Creo Parametric and other related applications Board of Directors PTC/USER International, RUG responsible Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 36,300 employees in 75 countries, and markets its products in more than 180 countries.

MBD Projects / Initiatives Using 3D annotations in early development phases as first input to tolerance analysis Dimensions and GD&T extracted from 3D to custom made tolerance analysis spread sheet Only used during the development phase. All specifications will be documented in 2D Drawings PE-Inspect extracts dimensions from 2D drawing to tolerance analysis sheet Status: Pilot project

Goals Goals: Save time – 2D drawings are not started when first tolerance stack up in done When 3D design are modified 2D drafters are not informed immediately and therefor 2D drawings are not updated accordingly. 3D annotations is visible to the designer Drivers: Tolerance analysis specialist and 2D drafters